LCP Health Analytics presence at the ISPE 2025 Annual Meeting
Health analytics Real world evidence generation Life sciences
The 41st ISPE Annual Meeting will be taking place at the Walter E. Washington Convention Center, between August 22 - 26. LCP Health Analytics are delighted to be attending and presenting our pioneering work at the leading conference for pharmacoepidemiology. It’s going to be a busy few days and we would love to connect with you whilst there!
Hot topic debate
Over the past 18 months, LCP Health Analytics have been developing cutting-edge applications of generative AI for real-world evidence (RWE) and pharmacoepidemiology. At the ISPE Annual Meeting, we will be presenting at a plenary session about the merits and pitfalls of using LLMs in pharmacoepidemiology activities, and the whether the field will change fundamentally as a result.
Dr Ben Bray, Evidence Generation Lead at LCP Health Analytics, will be joined by other expert panellists across industry, consultancy and academia to answer the ultimate question: can LLMs perform pharmacoepidemiology tasks as well (or better than) humans?
Date / Time: Tuesday, August 26, 3:00 – 4:00 pm ET
Location: Ballroom AB, Walter E. Washington Convention Center
We hope to see you there for a lively discussion!
Workshop presentations
Our team of specialists is also excited to be taking part in a practical, in-depth workshop exploring ‘The Future of Pharmacovigilance: Accelerating Signal Identification with Electronic Healthcare Data’. Dr Ben Bray, Evidence Generation Lead, will be joined by other expert panellists from industry, regulation and academia to explore how to augment existing pharmacovigilance systems with novel approaches utilising electronic healthcare data records.
Date / Time: Sunday, August 24, 5:15 pm – 6:45 pm ET
Location: 202 AB, Walter E. Washington Convention Center
Our team will also be presenting 10 posters on hot topics including drug-gene interactions, harmonizing standards in RWE and pregnancy drug safety studies.
Further details on poster titles and timings of sessions are below:
|
Poster title |
Poster session |
|
Prevalence of Drug-Gene Interactions Following Acute Myocardial Infarction: An Observational Study Using Data From the UK Biobank
|
|
|
Assessing core competencies in pharmacoepidemiology training programs: A Global Needs Assessment
|
|
|
Enhancing Pregnancy Drug Safety Studies: Expert Consensus on Methods and Definitions
|
|
|
An evidence base to support the establishment of a fit-for-purpose quality management system for secondary data pharmacoepidemiological studies
|
|
|
A fully automated AI-enabled pipeline for extracting Kaplan-Meier survival data from scientific plots |
|
|
Assessing the association between COVID-19 Vaccination and Thrombotic Thrombocytopenia Syndrome (ATTEST Study): Analysis of English Data 2020-2022
|
|
|
Safety Profile of Vaxzevria COVID-19 Vaccine in the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) |
|
|
Comparison of Primary Care Coded Prevalence of Atrial Fibrillation and Prescribing Rates for Drugs Indicated for Atrial Fibrillation Identified Using a Large-Language Model |
|
|
Harmonizing Standards: Recommendations for Mitigating Gaps in Real-World Evidence (RWE) Feasibility Guidance |
|
|
Risk of Venous Thrombosis with Thromboocytopenia Syndrome after vaccination with AZD1222: A European VAC4EU Post-authorisation Safety Study
|
|
Planning to attend?
Our experts are looking forward to meeting you there, including Dr Ben Bray, Evidence Generation Lead and Dr Ryan Chung, Consultant Biostatistician.
Please reach out to set up a coffee chat
Cannot make it but want to find out more about the work we are presenting?
We will be releasing more details about the posters and presentation following the conference.
In the meantime, please look take a look at case studies that showcase our work in RWE.
LCP Health Analytics partners with COTA to advance the use of US RWD to support HTA decision making internationally
Read nowThe associations between multimorbidity, healthcare resource utilisation and costs in individuals with Alzheimer's disease dementia
Read nowIncreasing comorbidities in patients with type 2 diabetes and implications for total morbidity and health system impacts health analytics life sciences
Read nowSubscribe to our thinking
Get relevant insights, leading perspectives and event invitations delivered right to your inbox.
Get started to select your preferences.
